Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the second leading cause of death by infectious disease after COVID-19 globally. The WHO estimates that in 2022 10.6 million people fell ill with TB and 1.3 million people died. Additionally, drug resistance in M. tuberculosis is an increasing problem1.
Rapid, accurate and accessible diagnostics would allow improvements for triage and treatment of patients with TB. Current diagnostic tests rely largely on potentially hard-to-obtain sputum samples or have long turnaround times. Host-response blood-based diagnostics are a current area of interest.